Back to search results

EmeTerm Device for Chronic Nausea and Vomiting

This study is testing if a wearable device called EmeTerm can help reduce chronic nausea and vomiting. The EmeTerm device is worn on the wrist and delivers low-frequency electrical stimulation to a nerve, which may help control nausea. Researchers want to see if using this device for 12 weeks reduces how often you experience moderate to severe nausea compared to your usual symptoms. They will also look at other symptoms like vomiting, abdominal pain, and how it affects your overall well-being. You might be able to join if you are 18 or older, have had nausea for over two months, can understand English, and receive care at The Ohio State University. The study is currently unclear about its recruitment status.

Study design
This is an interventional study planning to enroll 120 participants. It is being conducted at a single center.
What's involved
Participants will use the EmeTerm device for a 12-week treatment period. You will also need to complete online surveys using a smartphone or computer.
Compensation
Not stated in the trial record.
Follow-up
The primary outcome is measured at the end of the 12-week treatment period compared to a 2-week baseline period.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07720323

Evaluating Whether a Nausea Band Reduces Symptoms in Those With Chronic Nausea Vomiting

Recruiting
NAAges 18+InterventionalSupportive care
Ohio State University
~120 participants
Updated 2026-07-22 on ClinicalTrials.gov
What's tested:EmeTerm wearable TENS device

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in Average Weekly Frequency of Moderate to Severe Nausea
Measured over Baseline period (2 weeks) compared with the 12-week treatment period

Conditions

Chronic Nausea
Chronic Nausea and Vomiting Syndrome

Explore related trials

NauseaVomiting

Where it's being run

1 sites across 1 states
Ohio1

Study leadership

  • Subhankar CHAKRABORTY, MD, Ph.D. · PRINCIPAL_INVESTIGATOR · Ohio State University

Who to contact

SUBHANKAR CHAKRABORTY, M.D., Ph.D.
[email protected]
614-293-6255'
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Nausea present for more than 2 months. Age 18 years or older. Able to understand English. Receiving care at The Ohio State University. Able to complete online surveys using a smartphone or computer

Exclusion

Active treatment for cancer Current treatment for inflammatory bowel disease Cirrhosis End-stage renal disease Prior use of a wearable TENS unit for nausea Abdominal surgery within the previous 3 months Pregnancy (self-reported at enrollment) Current carpal tunnel syndrome Any contraindication to use of the EmeTerm device Inflammation, irritation, infection, ulceration, bleeding, open wounds, or other skin conditions near the wrist where the device is applied Presence of metallic implants in the body Head or facial injury within the previous 3 months Known brain tumor, meningitis, or stroke within the previous 3 months Cardiac pacemaker, implanted defibrillator, or other implanted metallic or electronic device History of seizures

What this trial measures

  • Change in Average Weekly Frequency of Moderate to Severe NauseaBaseline period (2 weeks) compared with the 12-week treatment period

    Participants will complete a daily nausea diary during the baseline period and during the 12-week treatment period. Each day, participants will report whether they experienced nausea and rate its severity as no nausea, mild nausea, moderate nausea (required medication to control symptoms), or severe nausea (not responding to current medications). The outcome will be calculated as the average weekly frequency of days with moderate or severe nausea during the treatment period compared with the baseline period.